Home/Filings/4/0001193125-25-311504
4//SEC Filing

Mainolfi Nello 4

Accession 0001193125-25-311504

CIK 0001815442other

Filed

Dec 7, 7:00 PM ET

Accepted

Dec 8, 6:09 PM ET

Size

8.3 KB

Accession

0001193125-25-311504

Insider Transaction Report

Form 4
Period: 2025-12-08
Mainolfi Nello
DirectorChief Executive Officer
Transactions
  • Exercise/Conversion

    Common Stock

    2025-12-08$2.08/sh+100,000$208,000760,482 total
  • Sale

    Common Stock

    2025-12-08$89.17/sh100,000$8,917,000660,482 total
  • Exercise/Conversion

    Stock Option (Right to Buy)

    2025-12-08100,000305,559 total
    Exercise: $2.08Exp: 2029-11-13Common Stock (100,000 underlying)
Footnotes (2)
  • [F1]These transactions were effected pursuant to a Rule 10b5-1 trading plan dated September 6, 2024 adopted by the reporting person.
  • [F2]The shares underlying this stock option are fully vested and exercisable.

Documents

1 file

Issuer

Kymera Therapeutics, Inc.

CIK 0001815442

Entity typeother

Related Parties

1
  • filerCIK 0001821189

Filing Metadata

Form type
4
Filed
Dec 7, 7:00 PM ET
Accepted
Dec 8, 6:09 PM ET
Size
8.3 KB